期刊文献+

内脂素与2型糖尿病患者炎症状态及内皮功能的关系 被引量:2

下载PDF
导出
摘要 目的探讨内脂素与2型糖尿病患者炎症和内皮功能的关系。方法初诊2型糖尿病患者98例,随机分为罗格列酮组和二甲双胍组各49例,分别给予罗格列酮和二甲双胍治疗12周,比较治疗前后各组体质指数(BMI)、腰臀比(WHR)、收缩压(SBP)、空腹血糖(FPG)、空腹胰岛素(FINS)、糖化血红蛋白(HbA1c)、血清胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL)、低密度脂蛋白胆固醇(LDL)、内脂素、hs-CRP、EDV等指标的变化。结果治疗后,两组FPG、FINS、HbA1c、HomaIR有明显下降(P<0.05);罗格列酮组内脂素、hs-CRP、EDV明显下降(P<0.05);二甲双胍组无明显变化。相关分析显示,内脂素与hs-CRP(r=0.41,P<0.05)、HbA1c(r=0.26,P<0.05)、HomaIR(r=0.33,P<0.05)、EDV(r=-0.56,P<0.05)相关,hs-CRP、EDV、HomaIR是影响血清内脂素水平的独立相关因素。结论罗格列酮可能通过降低血清内脂素发挥抗炎及改善内皮功能的作用。
出处 《广东医学》 CAS CSCD 北大核心 2010年第20期2684-2686,共3页 Guangdong Medical Journal
基金 河南省洛阳市科技计划项目(编号:040245)
  • 相关文献

参考文献7

  • 1FUKUHARA A,MATSUDA M,NISHIZAWA M,et al.Visfatin:A protein secreated by viscreral fat that mimics the effects of insulin[J].Science,2005,307(5708):426-430.
  • 2CHEN M P,CHUNG F M,CHANG D M,et al.Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus[J].J Clin Endocrinol Metab,2006,91(1):295-299.
  • 3MAYERSON A B,HUNDAL R S,DUFOUR S,et al.The effects of rosiglitazone on insulin sensitivity,lipolysis and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes[J].Diabetes,2002,51(3):797-802.
  • 4KIRPICHNIKOV D,MCFARLANE S L,SOWERS J R.Metformin:an update[J].Ann Intern Med,2002,137(1):25-33.
  • 5杨艳,杨刚毅,李伶,张凌,苗宗玉,卢春敏.内脂素对改善胰岛素抵抗及相关基因的作用[J].解放军医学杂志,2009,34(4):474-477. 被引量:8
  • 6ZHANG Y Y,GOTTARDO L,THOMPSON R,et al.A visfatin promoter pllymorphism is associated with low-grade inflammation and type 2 diabetes[J].Obesity,2006,14(12):2119-2126.
  • 7DEVARAJ S,XU D Y,JIALAL I.C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells:implications for the metabolic syndrome and atherothrombsis[J].Circulation,2003,107(3):398-440.

二级参考文献9

  • 1Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin:A protein secreted by visceral fat that mimics the effects of insulin. Science, 2005, 307(5708): 426
  • 2Pagano C, Pilon C, Olivieri M,et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab,2006, 91(8): 3165
  • 3Old K, Yamane K, Kamei N,et al. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endo crinol (Oxf), 2007, 67(5): 796
  • 4Li L, Ymag G, Li Q, et al. High-fat and lipid induced insulin resistmace in rats: the comparison of glucose metabolism, plasma resistin and adiponectin levels Ann Nutr Metab, 2006, 50(6):499
  • 5Staiger H, Hating Hid. Adipocytokines: fat-derived humoral media tots of metabolic homeostasis. Exp Clin Endocrinol Diab, 2005, 113 (2) : 67
  • 6Li L, Yang G, Li Q,et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endoerinol Diabetes,2006, 114 (10), 544
  • 7Hug C, Lodish HF. Medidne- Visfatin: a new adipokine. Science, 2005,307(5708) : 366
  • 8Wang P, Bouwman FG, Smit E, et al. The circulating PBEF/ NAMPT/visfatin level is associated with a beneficial blood lipid pro file. Pflugers Arch, 2007, 454(6): 971
  • 9Haider DG,Schaller G, Kapiotis S,et al. The release of the adipocy tokine visfatin is regulated by glucose and insulin. Diabetologia,2006, 49(8) :1909

共引文献7

同被引文献14

  • 1Herman WH, Zimmet P. Type 2 diabetes: an epidemic requiring global attention and urgent action [J]. Diabetes Care, 2012, 35(5): 943-944.
  • 2Murea M, Ma L, Freedman BI. Genetic and envi- ronmental factors associated with type 2 diabetes and diabetic vascular complications[J]. Rev Diabet Stud, 2012, 9(1):6-22.
  • 3Utsunomiya K. Treatment strategy for type 2 diabetes from the perspective of systemic vascular pro- tection and insulin resistance [J]. Vase Health Risk Manag, 2012, 8(2): 429-436.
  • 4Abbas A, Blandon J, Rude J, et al. PPAR-γ agonist in treatment of diabetes: cardiovascular safety considerations[J]. Cardiovasc Hematol Agents Med Chem, 2012, 10(2): 124-134.
  • 5Bird SR, Hawley JA. Exercise and type 2 diabetes: new prescription for an old problem [J]. Maturitas, 2012 , 72(4): 311-316.
  • 6Kadoglou NP, Sailer N, Kapelouzou A, et al. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes[J]. Acta Diabetol, 2012, 49 (4): 269- 276.
  • 7Wan Y, Evans RM. Rosiglitazone activation of PPAR gamma suppresses fractalkine signaling [J]. J Mol Endocrinol, 2010, 44(2) : 135-142.
  • 8Norwood P, Liutkus JF, Haber H, et al. Safety of exenatide once weekly in patients with type 2 dia betes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years [J]. Clin Ther, 2012, 34(10): 2082-2090.
  • 9Kikuchi M, Kaku K, Odawara M, et al. Efficacy and tolerability of rosiglitazone and pioglitazone in drug-naive Japanese patients with type 2 diabetes mellitus: a double-blind, 28 weeks' treatment, comparative study [J]. Curr Med Res Opin, 2012, 28(6) : 1007-1016.
  • 10Gunduz FO, Yildirmak ST, Temizel M, et al. Serum visfatin and fetuin-a levels and glycemic control in patients with obese type 2 diabetes mellitus [J]. Diabetes Metab J, 2011, 35(5): 523-528.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部